<DOC>
	<DOCNO>NCT01764425</DOCNO>
	<brief_summary>Clinical trial study safety tolerability , pharmacokinetics , food effect pharmacodynamics new compound P7435 healthy , overweight and/or obese subject</brief_summary>
	<brief_title>Clinical Trial Study Safety Tolerability , Pharmacokinetics , Food Effect &amp; Pharmacodynamics New Compound P7435 Healthy , Overweight and/or Obese Subjects</brief_title>
	<detailed_description>- A phase I , randomize , double-blind , placebo-controlled , dose escalate study P7435 determine safety , tolerability , pharmacokinetics , food effect pharmacodynamics single multiple ascend dos P7435 . - Subjects participate either healthy subject healthy overweight and/or obese subject . In study , overweight/obese define subject BMI 23 kg/m2 . - The study conduct 3 part follow : Part A consist Single Ascending Dose ( SAD ) study , Part B consist Multiple Ascending Dose ( MAD ) study Part C consist Food Effect study .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>Willingness able provide write informed consent participate study . Healthy adult male subject age 18 45 ( inclusive ) year old BMI 19 23 kg/m2 . Overweight ( BMI 23 25kg/m2 ) and/or obese ( BMI 25 35 kg/m2 ) otherwise healthy subject PartB . Healthy determine investigator Smoking le 10 cigarette per day able refrain smoking confinement . Ability willingness abstain alcohol , methylxanthinecontaining beverage food ( coffee , tea , coke , chocolate , `` power drink '' ) grapefruit juice admission . Employees sponsor clinical site . Female subject . No past current serious disease organ allow . Exceptions may nonmalignant skin disease , childhood asthma condition per Investigator 's discretion discuss Sponsor priori . History significant gastrointestinal disease significant diseases include cardiac , renal liver impairment . History sleep apnea , irregular sleep/wake cycle work night shift . Acute disease state History hypo/hyperthyroidism repeat abnormal TSH value screen obesity endocrine origin . History alcoholism 2 year Positive serology human immunodeficiency virus ( HIV1/2 ) antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus ( HCV ) antibody . Positive finding urine drug screen / alcohol breath test . Participation another clinical trial within 90 day first drug administration . Intake 810 cup coffee and/or tea per day consumption methyl xanthinecontaining beverage ( tea , coffee , cola drink , chocolate ) within 48 hour prior study . Donation blood ( i.e . 350 ml ) within 90 day Day 1 first treatment period .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>P7435</keyword>
	<keyword>Healthy , overweight obese subject</keyword>
	<keyword>Single ascend dose</keyword>
	<keyword>Multiple ascend dose</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>